3582

Quantitative and qualitative parameters of DCE-MRI predict CDKN2A/B homozygous deletion in gliomas
Huiquan Yang1, Zhengyang Zhu1, Xin Zhang1, and Bing Zhang1
1Nanjing Drum Dower Hospital, Nanjing, China

Synopsis

Keywords: Tumors (Pre-Treatment), Tumor

Motivation: Homozygous deletion (HD) of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) holds important prognostic value in gliomas.

Goal(s): This study aims to explore the predictive potential of conventional MRI imaging parameters combined with dynamic contrast-enhanced (DCE) MRI parameters in predicting CDKN2A/B HD status in gliomas.

Approach: Conventional MRI features and DCE-MRI qualitative parameter time-intensity curve types, quantitative parameters Ktrans, Kep, Ve, Vp, and iAUC were obtained. Logistic regression models for prediction of CDKN2A/B HD status were constructed.

Results: Ktrans can serve as valuable predictive parameters for identifying CDKN2A/B HD status in all glioma patients as well as patients with IDH-mutant or IDH-wild gliomas.

Impact: Our findings provide a foundation for precise preoperative non-invasive diagnosis and personalized treatment approaches for glioma patients.

Purpose: Homozygous deletion (HD) of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) holds important prognostic value in gliomas1,2. This study aims to explore the predictive potential of conventional MRI imaging parameters combined with dynamic contrast-enhanced (DCE) MRI parameters in predicting CDKN2A/B HD status in gliomas.
Methods: Preoperative MRI data of 105 patients (69 without CDKN2A/B HD, and 36 with CDKN2A/B HD) with gliomas were retrospectively collected. Conventional MRI features and DCE-MRI qualitative parameter time-intensity curve (TIC) types, quantitative parameters Ktrans, Kep, Ve, Vp, and iAUC were obtained. Logistic regression models for prediction of CDKN2A/B HD status were constructed in all gliomas as well as subtypes of IDH-mutant and IDH-wild gliomas. Performance of predictive models was quantified using area under receiver operating characteristic curve (AUC).
Results: Multivariate analysis for all patients demonstrated that age (OR = 1.103, p = 0.002) and Ktrans (OR = 1.051, p < 0.001) independently predicted CDKN2A/B HD. In IDH-mutant subgroup, multivariate analysis results indicated that Ktrans (OR = 1.098, p = 0.031) emerged as autonomous predictors of CDKN2A/B HD. In IDH-wild subgroup, age (OR = 1.111, p = 0.002) and Ktrans (OR = 1.032, p = 0.001) were independent predictors of CDKN2A/B HD according to multivariate analysis. The AUCs of the corresponding models were 0.90, 0.95 and 0.84, respectively.
Conclusion: Ktrans can serve as valuable predictive parameters for identifying CDKN2A/B HD status in all glioma patients as well as patients with IDH-mutant or IDH-wild gliomas. These findings provide a foundation for precise preoperative non-invasive diagnosis and personalized treatment approaches for glioma patients.
Limitations: This study was retrospective and relied on a relatively limited dataset collected from a single center. Survival prediction analysis was not performed in our study.

Acknowledgements

Funding: This research was funded by National Science and Technology Innovation 2030 -- Major program of "Brain Science and Brain-Like Research" (2022ZD0211800), Project of China Hospital Reform and Development Research Institute, Nanjing University (Aid project of Nanjing Drum Tower Hospital Health, Education & Research Foundation) (2022-LCYJ-MS-25), China Postdoctoral Science Foundation (2023M731627).

Institutional Review Board Statement: This study received approval from both the Medical Research Ethics Committee and the Institutional Review Board of the Affiliated Drum Tower Hospital of Nanjing University Medical School (Protocol number 2022-364-02).

References

1. Tesileanu CMS, Vallentgoed WR, French PJ, van den Bent MJ (2022) Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: a systematic review. Eur J Cancer 175:214–2232.

2. Yang J, Li L, Luo T, Nie C, Fan R, Li D et al (2023) Cyclin-dependent kinase inhibitor 2A/B homozygous deletion prediction and survival analysis. Brain Sci 13(4):548

Figures

Fig. 1 Representative MRI images of a 56-year-old male, IDH-wild glioma with CDKN2A/B HD. (A) T1CE; (B) T2WI; (C) DWI; (D) ADC; (E) TIC, type Ⅱ; (F) Ktrans; (G) Kep; (H) Ve; (I) Vp; (J) iAUC.

Fig. 2 Representative MRI images of a 55-year-old female, IDH-mutant glioma without CDKN2A/B HD. (A) T1CE; (B) T2WI; (C) DWI; (D) ADC; (E) TIC, type Ⅲ; (F) Ktrans; (G) Kep; (H) Ve; (I) Vp; (J) iAUC.

Fig. 3 Examples of NGS and FISH for HD status of CDKN2A/B in gliomas. (A) Copy number variation profile of genes detected in a case without CDKN2A/B HD; (B) Copy number variation profile of genes detected in a case with CDKN2A/B HD; (C) Representative FISH picture of glioma cells without CDKN2A/B HD; (D) Representative FISH picture of glioma cells with CDKN2A/B HD. Bar: 10 μm.

Fig 4. Establishment and validation of the predictive model of CDKN2A/B HD status in gliomas. ROC curve (A) and nomogram (B) of the model in all gliomas; ROC curve (C) and nomogram (D) of the model in the subgroup of IDH-mutant gliomas; ROC curve (E) and nomogram (F) of the model in the subgroup of IDH-wild gliomas.

Proc. Intl. Soc. Mag. Reson. Med. 32 (2024)
3582
DOI: https://doi.org/10.58530/2024/3582